Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2008

View Archived Issues

Ranbaxy receives Indian approval for phase III clinical trial of antimalaria drug RBx-11160

Toxicity of antispastic agent azumolene evaluated in vivo

New antimicrobial agents reported in recent patent literature

Oramed launches phase Ia insulin suppository trial

Novel agents for cardiovascular disorders disclosed in recent patents

Early results from first clinical study of JNJ-26854165 reported

Oxygen to conduct safety and efficacy clinical trial of Oxycyte in TBI

Anti-VEGFR-1 monoclonal antibody IMC-18F1 well tolerated thus far in phase I study

Columbia signs collaboration agreement with NIH for phase III PREGNANT study of Prochieve

Activity of anticancer CDK inhibitor AZD-5597 described

Calando completes phase I clinical study of IT-101 in inoperable or metastatic tumors

Pramiconazole demonstrates efficacy in vulvovaginal yeast infections

Activity of potent PI3K inhibitor GSK-615 disclosed

New treatment options for gastrointestinal disorders imparted in recent patents

Recent Biovitrum and Merck patents describe new therapeutic agents for obesity

Phenomix and Forest sign development and commercialization agreement for dutogliptin

GSK and Affiris sign exclusive license and option agreement for therapeutic AD vaccines

FDA approves Alchemia's IND application for phase III clinical trials of HyCAMP

SkyePharma announces successful completion of phase III study of Flutiform

Astellas withdraws European MAA for telavancin and plans resubmission

Johnson & Johnson submits NDA to FDA for carisbamate

EMEA issues positive opinion for Lunivia MAA in Europe

Further clinical trials suspended for GRC-6211 in osteoarthritis pain

Astellas' Graceptor launched in Japan

CHMP adopts negative opinion on Cymbalta for the treatment of fibromyalgia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...